BSECompany Update26 Aug 2026 · 26 Aug 2026, 08:35 am

Announcement under regulation 30

Tavexia Lifecare Ltd · 539519

✦ AI Summary▲ PositiveExpansion

Tavexia Lifecare Ltd has expanded into the pharmaceutical business as a new growth vertical, strengthening its presence in the healthcare and lifecare ecosystem. The company plans to explore opportunities across the pharmaceutical value chain, including pharmaceutical products, APIs, intermediates, specialty chemicals, nutraceuticals, and related manufacturing opportunities.

Analysis Scores

Earnings Impact6/10
Growth Catalyst8/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk2/10
Liquidity Impact8/10
Market Sentiment7/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Tavexia Lifecare Ltd - 539519 - Announcement Under Regulation 30

Attachments (1)

📄

ae1a5b04-1e72-4a76-a58e-b50d73be344e.pdf

pdf

Download →
View document text
TAVEXIA LIFECARE LIMITED (FORMERLY SATTVA SUKUN LIFECARE LIMITED) CIN: L27509MH1980PLC329224 Date: 26/08/2026 BSE Ltd. Phiroze Jeejeebhoy Towers Dalal Street, Fort, Mumbai - 400 001 Scrip Code: 539519 Subject: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Tavexia Lifecare Expands Business with Entry into Pharmaceuticals as New Growth Vertical Dear Sir/Madam, Tavexia Lifecare Expands Business with Entry into Pharmaceuticals as New Growth Vertical Strategic expansion strengthens the Company’s growth and diversification strategy while building on its core lifecare business. Mumbai, August 26, 2026: Tavexia Lifecare Limited has expanded into the pharmaceutical business as an additional growth vertical, strengthening its broader presence in the healthcare and lifecare ecosystem. The move forms part of the Company’s growth and diversification strategy while its existing lifecare business remains at the core of its operations. The Company plans to explore opportunities across the pharmaceutical value chain, including pharmaceutical products, active pharmaceutical ingredients (APIs), intermediates, specialty chemicals, nutraceuticals and related manufacturing opportunities. The new vertical is intended to complement Tavexia’s existing lifecare operations and provide additional avenues for business expansion. The expansion comes at a time of strong growth in India’s pharmaceutical sector. The Indian pharmaceutical market is currently valued at around US$60 billion and is projected to reach approximately US$130 billion by 2030. India’s pharmaceutical exports reached around US$30.47 billion in FY2024-25, highlighting the country’s growing importance in global healthcare and pharmaceutical supply chains. For Tavexia, the addition of pharmaceuticals provides an opportunity to diversify its revenue base while leveraging the broader growth of India’s healthcare sector. The Company believes that its new pharmaceutical vertical, complementing the existing lifecare business, can create greater opportunities for partnerships, product development and long-term business growth. Mumbai Office: Plot No. 2B/1, Ground Floor, Kandivali Cooperative Industrial Estate Ltd., Hindustan Naka, Kandivali (West), Mumbai - 400067 Tel: +91-22-2868 4491 | Email: info@mayukh.co.in & sattvasukunlifecarelimited@gmail.com| Website: www.mayukh.co.in & https://sattvasukun.co.in/ TAVEXIA LIFECARE LIMITED (FORMERLY SATTVA SUKUN LIFECARE LIMITED) CIN: L27509MH1980PLC329224 Commenting on the development, Mr. Mit Tarunkumar Brahmbhatt, Chairman and Managing Director, Tavexia Lifecare Limited, said: “Our core lifecare business remains central to Tavexia’s growth journey, and the addition of pharmaceuticals is a natural extension of our presence in the broader healthcare ecosystem. India’s pharmaceutical sector presents significant opportunities, and we see potential to build an additional growth engine alongside our existing operations. Our focus will remain on disciplined execution, developing sustainable business capabilities and creating long-term value for our shareholders and stakeholders.” The Company will continue to focus on strengthening its existing lifecare operations while evaluating pharmaceutical opportunities based on market potential, commercial viability and long-term strategic value. The addition of the pharmaceutical vertical is expected to broaden Tavexia's addressable market and provide a more diversified platform for future growth, while maintaining the Company’s core focus on lifecare. About Tavexia Lifecare Limited Tavexia Lifecare Limited is a healthcare-focused company with its core business centred on lifecare. As part of its growth and diversification strategy, the Company has expanded into the pharmaceutical sector as an additional business vertical. Through its existing lifecare business and newly added pharmaceutical vertical, Tavexia aims to build a broader healthcare platform and pursue sustainable growth opportunities across the evolving Indian healthcare ecosystem. For further information, please contact: Corporate Communications Tavexia Lifecare Limited Please take the same on your record and acknowledge the receipt of the same. Thanking You, Yours Faithfully For Tavexia Lifecare Limited (Formerly Sattva Sukun Lifecare) Mif Tarunkumar Brahmbhatt Managing Director Din: 06520600 ‘Mumbal Office: Plot No. 2B/1, Ground Floor, Kandivali Cooperative Industrial Estate Ltd., Hindustan Naka, Kandivali (West), Mumbai - 400067 Tel: +91-22-2868 4491 | Email: info@mayukh.co.in & sattvasukunlifecarelimited@gmail.com| ‘Website: www.mayukh.co.in & https://sattvasukun.co.in/